BY MARKETWIRE
-
Novo Nordisk focuses on scaling up in China, France and the US
Novo Nordisk will certainly concentrate on labor force development in China, France and the United States, claims CFO.
-
WSA sees room for earnings improvement: Better prices and strong growth to ensure progress
” We are still certain in our capability to considerably boost margins,” states WS Audiology’s CFO.
-
Lundbeck completes Longboard acquisition as deal expected to close next week
The overall deal has a worth of roughly USD 2.6 bn and will certainly set you back Lundbeck roughly USD 2.5 bn.
-
Leo Pharma’s chairman finds an IPO in 2026 realistic
When Leo Pharma’s chairman of the board, Jesper Brandgaard, took over in 2021, it was a loss-making business. ”I was surprised at how bad the finances were,” he says.
-
Audientes accused – again – of misleading investors
The hearing business’s monitoring has actually been called undependable, yet chief executive officer Steen Thygesen has actually not reacted or talked about the accusations.
-
Obesity drugs increasingly appear on reimbursement lists of US employers
However high costs are an obstacle, according to a record from the Mercer working as a consultant.
-
GN gained market share in sales to US veterans in October — Demant’s share decreased
In general, sales of listening device and hearing systems with VA raised to USD 39.1 m in October, up from USD 37.6 m in September.
-
KM Biologics’ mpox vaccine approved by WHO
Previously, just Bavarian Nordic had actually an authorized vaccination on the marketplace.
-
Novo Nordisk continues to see strong appetite for weight loss drugs in the US, says UK bank
According to Novo Nordisk, minimal supply is the only point keeping back the sales growth of fat burning items in the United States.
-
Sonova reports decent growth in difficult market – but operations are lagging
Sales in the initial haly-year expanded to CHF 1,833.2 m (USD 2.1 bn) from CHF 1,753 m in the very same duration in 2015.
